Sorry, you need to enable JavaScript to visit this website.

Dosing Pathways | INVEGA HAFYERA™ (paliperidone palmitate) HCP

INVEGA HAFYERA™ Offers Fewer Doses for a Life Less Defined by Their Schizophrenia Treatment1

356 daily oral antipsychotic doses a year versus 2 INVEGA HAFYERA™ doses a year

Start INVEGA SUSTENNA® Earlier in the Treatment Journey to Put Patients on a Path to Just 2 Doses a Year

Treatment path 1: oral antipsychotic, one injection a month for at least 4 months
  • Must be adequately treated for at least 4 months with INVEGA SUSTENNA® to transition to INVEGA HAFYERA™
  • It is recommended that the last 2 doses of INVEGA SUSTENNA® be the same strength (156 mg or 234 mg) before starting INVEGA HAFYERA™.
Must be adequately treated with at least one 3-month injection cycle of INVEGA TRINZA® at doses of 546 mg or 819 mg to transition to INVEGA HAFYERA™
  • Must be adequately treated for at least 4 months with INVEGA SUSTENNA® to transition to INVEGA TRINZA®
  • Must be adequately treated with at least one 3-month injection cycle of INVEGA TRINZA® at doses of 546 mg or 819 mg to transition to INVEGA HAFYERA™

A Seamless Dosing Pathway to INVEGA HAFYERA™

Dosing pathway to INVEGA HAFYERA™ chart
  • INVEGA HAFYERA™ is to be used only after adequate treatment has been established with INVEGA SUSTENNA® for at least 4 months (with the last 2 doses being 156 mg or 234 mg), or INVEGA TRINZA® for at least one 3-month injection cycle (at doses of 546 mg or 819 mg)
  • There are no equivalent doses of INVEGA HAFYERA™ for the 39 mg, 78 mg, or 117 mg doses of INVEGA SUSTENNA®, which were not studied
  • There are no equivalent doses of INVEGA HAFYERA™ for the 273 mg or 410 mg doses of INVEGA TRINZA®, which were not studied

REFERENCE: 1. INVEGA HAFYERA™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2021.

For patients being treated with oral antipsychotics, start their journey to INVEGA HAFYERA™ by initiating treatment with INVEGA SUSTENNA®